• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of gynaecological oncology >Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
【24h】

Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.

机译：重度治疗的复发性卵巢癌，腹膜癌和输卵管癌患者每周进行单药卡铂治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE OF INVESTIGATION: To report the experience of a single institution in the south of Israel with weekly carboplatin in heavily pretreated patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma. METHODS: The hospital records of ten patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma who had 2nd-line or later chemotherapy with weekly carboplatin between January 2003 and December 2004 were retrospectively reviewed. Weekly carboplatin, at a dose calculated with use of the Hilary Calvert's formula at AUC = 2, was given intravenously in 500 ml dextrose 5% over 30 minutes on day 1 of every seven days. Response was determined using clinical evaluation, radiological reports and CA-125 level. Toxicity was graded using the National Cancer Institute (NCI) criteria. RESULTS: Overall, 155 courses of weekly carboplatin were given. The median number of courses per patient was 14 (range, 2-37) and median duration of treatment was 22.5 (range, 2-40) weeks. Four patients (40%) had complete response lasting for 8-20 (median, 12) weeks, two (20%) had partial response lasting for five and 14 weeks, respectively, one (10%) had stable disease lasting for 23 weeks and three (30%) had progressive disease. Toxicity was mainly hematological with only grade 1-2 hematological toxicity as follows: anemia--four patients (40%), leukopenia--three (30%), neutropenia--three (30%) and thrombocytopenia--two (20%). CONCLUSION: Weekly carboplatin has considerable activity and low and well tolerated toxicity in heavily pretreated patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma.
机译：调查的目的：报告在铂金敏感的复发性卵巢癌，腹膜癌和输卵管癌的经过大量预处理的患者中，以色列南部一家单一机构每周接受卡铂的经历。方法：回顾性分析2003年1月至2004年12月期间每周进行二线或以后的卡铂化疗的10例铂敏感型复发性卵巢癌，腹膜癌和输卵管癌患者的医院记录。在每7天的第1天的30分钟内，以500 ml葡萄糖5％静脉注射每周卡铂，剂量使用AUC = 2的希拉里·卡尔弗特公式计算。使用临床评估，放射学报告和CA-125水平确定反应。毒性根据美国国家癌症研究所（NCI）标准进行分级。结果：总体上，每周进行155个疗程的卡铂。每位患者的中位疗程数为14（范围2-37），中位疗程为22.5（范围2-40）周。 4名患者（40％）的完全缓解持续了8-20（中位数，12）周，其中2（20％）的部分缓解持续了5和14周，其中1（10％）的疾病稳定了持续了23周三名（30％）患有进行性疾病。毒性主要是血液学，只有1-2级血液学毒性，如下：贫血-四名患者（40％），白细胞减少症-三名（30％），中性粒细胞减少症-三名（30％）和血小板减少症-两名（20％） ）。结论：在对铂敏感的复发性卵巢癌，腹膜癌和输卵管癌的大量预处理患者中，每周卡铂具有相当的活性，且毒性低且耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号